Hikma unveils generic Halcion

Press enter to search
Close search
Open Menu

Hikma unveils generic Halcion

By Sandra Levy - 11/19/2018
Hikma Pharmaceuticals has launched triazolam tablets in 0.125- and 0.25-mg dosage strengths.

The product is the generic version of Pfizer’s Halcion.

Hikma’s triazolam tablets are indicated for the short-term treatment of insomnia, which is generally 7-to-10 days. Use of the product for more than two or three weeks requires a complete reevaluation of the patient, according to the company.

Triazolam tablets had a market value of approximately $27 million in the 12 months ended September 2018, according to IQVIA.

“We are excited to launch triazolam tablets, improving patients’ access to this product. This launch highlights the successful execution of our strategy to develop more differentiated products by leveraging our specialized manufacturing capabilities,” Hikma generic division president Brian Hoffmann said.

Related Topics